ClinicalTrials.gg
RecruitingNCT07344779ROADUpdated Oct 19, 2026

A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice

An observational study in Metastatic Hormone-Sensitive Prostate Cancer, sponsored by Bayer. Recruiting at 16 sites in 16 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 19, 2026Now RecruitingEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,600
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 75 studies in Prostatic Neoplasms by Bayer — 11 open to participants now, 16 under way, 1 of them phase 3. Prostatic Neoplasms · Bayer.

Planned enrollment
8th of 40
1,600 · median 700
Started
2026
with 5 others
Observational
40 of 75
8 open now
Primary completion
2029-12
later than 12 of 15 live
Registered
70th of 75
by date

Among the 75 studies in Prostatic Neoplasms by Bayer, this one is the 8th largest by planned enrollment of the 40 observational ones that give a count, is one of 6 that started in 2026, is one of 40 observational ones, reaches primary completion later than 12 of the 15 other live ones, and was the 70th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

11 of the 75 studies in Prostatic Neoplasms by Bayer are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Prostatic Neoplasms by Bayer, or all of them as a file.
02

Study summary

This is an international, prospective, open-label, multicenter, multi-cohort, non-interventional observational study designed to describe the real-world effectiveness and safety of darolutamide in combination with androgen deprivation therapy (ADT), with or without docetaxel, in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aims to enroll approximately 1,600 male patients (800 per cohort) from multiple countries, primarily in Europe, who have a diagnosis of mHSPC and for whom a decision to treat with darolutamide has been made by the treating physician prior to enrollment. The primary objective is to estimate the proportion of patients achieving undetectable prostate-specific antigen (PSA) levels (\<0.2 ng/mL) at 1 year of treatment in each cohort. Secondary objectives include describing patient demographics, clinical characteristics, prior and concomitant treatments, adverse events, and clinical effectiveness measures such as overall survival, time to new treatment, time to castration resistance, and time to PSA progression. Further objectives involve assessing quality of life, reasons for not adding docetaxel, outcomes by patient subgroups (e.g., Gleason score, disease volume, ECOG status), genomic testing results, and hospitalization rates. Data will be collected using electronic case report forms (eCRF) during routine clinical practice, with no additional diagnostic or monitoring procedures required beyond standard care. All patients must provide informed consent prior to participation. The study will comply with applicable regulatory requirements, including IEC/IRB approval in all participating countries. Statistical analyses will be descriptive and exploratory, with interim analyses planned after 200, 400, and 600 patients per cohort have completed at least 12 months of treatment or discontinued therapy. The study is expected to provide valuable insights into the real-world use of darolutamide in mHSPC, supporting clinical decision-making and enhancing understanding of treatment patterns, effectiveness, and safety in diverse patient populations.

03

Conditions studied

  • Metastatic Hormone-Sensitive Prostate Cancer

Browse trials for

Keywords

  • Prostatic Neoplasms, Hormone-Sensitive/Metastatic Prostate Cancer
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male patients with a diagnosis of metastatic hormone-sensitive prostate cancer (mHSPC) for whom a decision to treat with darolutamide has been made by the treating physician prior to enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patient with a diagnosis of mHSPC
  • Male aged ≥18 years (or country's legal age of adulthood if >18 years)
  • or cytologically confirmed adenocarcinoma of prostate; may have begun ADT (up to 120 days prior to enrollment)
  • disease by conventional or new generation imaging
  • Decision to initiate treatment with darolutamide with or without docetaxel made prior to enrollment
  • Signed informed patient consent before start of data collection
  • of ≥3 months based on clinical judgment

Exclusion criteria

Exclusion Criteria:

  • Participation in an program with interventions outside of routine clinical practice
  • according to local marketing authorization
  • Any prior treatment with second-generation androgen receptor (AR) inhibitors such as enzalutamide, apalutamide, or other investigational AR inhibitors, cytochrome P17 enzyme inhibitor (except prior abiraterone acetate if discontinued at least 24 months before diagnosis) or other investigational CYP 17 enzyme inhibitors as antineoplastic treatment for prostate cancer.
  • Prior hormone therapy in the metastatic setting
  • Treatment with darolutamide initiated more than 7 days prior to enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Darolutamide + ADT + Docetaxel (Triplet therapy)

    This group includes men with metastatic hormone-sensitive prostate cancer (mHSPC) who are treated with a combination of darolutamide, androgen deprivation therapy (ADT), and docetaxel. The decision to use this triplet therapy is made by the treating physician as part of routine clinical practice before the patient enrolls in the study. Patients in this cohort receive all three treatments according to local standard of care.

    Drug: Darolutamide (BAY 1841788) · Drug: ADT · Drug: Docetaxel

  • Darolutamide + ADT (Doublet therapy)

    This group includes men with metastatic hormone-sensitive prostate cancer (mHSPC) who are treated with darolutamide and androgen deprivation therapy (ADT), but without docetaxel. The decision to use this doublet therapy is made by the treating physician as part of routine clinical practice before the patient enrolls in the study. Patients in this cohort receive darolutamide and ADT according to local standard of care.

    Drug: Darolutamide (BAY 1841788) · Drug: ADT

Interventions

  • DrugDarolutamideStudies of DarolutamideDarolutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Darolutamide administered per local standard of care in combination with ADT.

    Also known as: NUBEQA

  • DrugAntiandrogensStudies of AntiandrogensAntiandrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Androgen deprivation therapy administered per local standard of care.

  • Docetaxel administered per local standard of care in combination with darolutamide and ADT for cohort 1.

06

What researchers measure

Primary outcomes

  1. Proportion of patients in cohort 1 achieving undetectable PSA (<0.2 ng/mL) at 1 year

    To describe the effectiveness of darolutamide + ADT + docetaxel in patients with mHSPC by means of estimating the prostate-specific antigen (PSA) undetectable rates (PSA\<0.2 ng/mL) after 1 year of study treatment.

    Time frame: after 1 year of treatment

  2. Proportion of patients in cohort 2 achieving undetectable PSA (<0.2 ng/mL) at 1 year

    To describe the effectiveness of darolutamide + ADT in patients with mHSPC by means of estimating the prostate-specific antigen (PSA) undetectable rates (PSA\<0.2 ng/mL) after 1 year of study treatment.

    Time frame: after 1 year of treatment

Secondary outcomes

  1. Overall survival per cohort and per country

    Time from start of darolutamide treatment until death from any cause.

    Time frame: up to 4 years

  2. Overall survival per cohort in all countries

    Time from start of darolutamide treatment until death from any cause.

    Time frame: up to 4 years

  3. Time to subsequent treatment per cohort and per country

    Time from start of darolutamide treatment to initiation of a new anti-cancer therapy.

    Time frame: up to 4 years

  4. Time to subsequent treatment per cohort in all countries

    Time from start of darolutamide treatment to initiation of a new anti-cancer therapy.

    Time frame: up to 4 years

  5. Time to castration resistance (CRPC) per cohort and per country

    Time from enrollment until documented clinical or PSA progression with testosterone level \<50 ng/dL or documented medical/surgical castration.

    Time frame: up to 4 years

  6. Time to castration resistance (CRPC) per cohort in all countries

    Time from enrollment until documented clinical or PSA progression with testosterone level \<50 ng/dL or documented medical/surgical castration.

    Time frame: up to 4 years

  7. Time to PSA progression per cohort and per country

    Time from start of darolutamide treatment to PSA progression (≥25% increase above nadir and ≥2 ng/mL, confirmed by a second value ≥3 weeks later, but prior to 6 months, while on treatment).

    Time frame: up to 4 years

  8. Time to PSA progression per cohort in all countries

    Time from start of darolutamide treatment to PSA progression (≥25% increase above nadir and ≥2 ng/mL, confirmed by a second value ≥3 weeks later, but prior to 6 months, while on treatment).

    Time frame: up to 4 years

  9. PSA response rate per cohort and per country

    Proportion of patients with blood PSA level \<0.2 ng/mL, confirmed by a second subsequent PSA value \<0.2 ng/mL 3 or more weeks later

    Time frame: 1 year

  10. PSA response rate per cohort in all countries

    Proportion of patients with blood PSA level \<0.2 ng/mL, confirmed by a second subsequent PSA value \<0.2 ng/mL 3 or more weeks later

    Time frame: 1 year

  11. Survival rate per cohort and per country

    Survival rate at specified time points.

    Time frame: up to 4 years

  12. Survival rate per cohort and all countries

    Survival rate at specified time points.

    Time frame: up to 4 years

  13. Time to discontinuation per cohort and per country

    Time from start of darolutamide treatment to permanent discontinuation or death

    Time frame: up to 4 years

  14. Time to discontinuation per cohort in all countries

    Time from start of darolutamide treatment to permanent discontinuation or death

    Time frame: up to 4 years

  15. Reason for discontinuation percohort and per country

    Reason for permanent darolutamide discontinuation

    Time frame: up to 4 years

  16. Reason for discontinuation per cohort in all countries

    Reason for permanent darolutamide discontinuation

    Time frame: up to 4 years

  17. Patient demographics per cohort and per country

    Demographic characteristics at the first documented regular visit ion the study, referred to as baseline).

    Time frame: at baseline

  18. Patient demographics per cohort in all countries

    Demographic characteristics at the first documented regular visit ion the study, referred to as baseline).

    Time frame: at baseline

  19. Medical History per cohort and per country

    The medical history will be documented at study start.

    Time frame: at baseline

  20. Medical History per cohort in all countries

    The medical history will be documented at study start.

    Time frame: at baseline

  21. Concomitant medication per cohort and per country

    Documentation of Concomitant medication.

    Time frame: up to 4 years

  22. Concomitant medication per cohort in all countries

    Documentation of Concomitant medication.

    Time frame: up to 4 years

  23. Concomitant treatment per cohort and per country

    Documentation of Concomitant treatments.

    Time frame: up to 4 years

  24. Concomitant treatment per cohort in all countries

    Documentation of Concomitant treatments.

    Time frame: up to 4 years

  25. Darolutamide use per cohort and per country

    To describe real-world use of darolutamide in mHSPC patients.

    Time frame: up to 4 years

  26. Darolutamide use per cohort in all countries

    To describe real-world use of darolutamide in mHSPC patients.

    Time frame: up to 4 years

  27. Diagnostic Imaging Technology per cohort and per country

    Documentation of Diagnostic Imaging Technology at the initial study visits (baseline).

    Time frame: at baseline

  28. Diagnostic Imaging Technology per cohort in all countries

    Documentation of Diagnostic Imaging Technology at the initial study visits (baseline).

    Time frame: at baseline

  29. Adverse events per cohort and per country

    Number of all adverse events.

    Time frame: up to 4 years

  30. Adverse events per cohort in all countries

    Number of all adverse events.

    Time frame: up to 4 years

  31. Serious Adverse events per cohort and per country

    Number of all serious adverse events.

    Time frame: up to 4 years

  32. Serious Adverse events per cohort in all countries

    Number of all serious adverse events.

    Time frame: up to 4 years

  33. Drug-related Adverse events per cohort and per country

    Number of all drug-related (darolutamide) adverse events.

    Time frame: up to 4 years

  34. Drug-related Adverse events per cohort in all countries

    Number of all drug-related (darolutamide) adverse events.

    Time frame: up to 4 years

  35. Serious Drug-related Adverse events per cohort and per country

    Number of all serious drug-related (darolutamide) adverse events.

    Time frame: up to 4 years

  36. Serious Drug-related Adverse events per cohort in all countries

    Number of all serious drug-related (darolutamide) adverse events.

    Time frame: up to 4 years

  37. Adverse events leading to treatment discontinuation per cohort and per country

    Number of adverse events leading to treatment discontinuation.

    Time frame: up to 4 years

  38. Adverse events leading to treatment discontinuation per cohort in all countries

    Number of adverse events leading to treatment discontinuation.

    Time frame: up to 4 years

  39. Vital Signs: Blood Pressure per cohort and per country

    Blood Pressure is measured in mmHg throughout the study, at all major visit types, over the full observation period.

    Time frame: up to 4 years

  40. Vital Signs: Blood Pressure per cohort in all countries

    Blood Pressure is measured in mmHg throughout the study, at all major visit types, over the full observation period.

    Time frame: up to 4 years

  41. Vital Signs: Body Temperature per cohort and per country

    Body Temperature is measured in degrees Celsius (°C) or Fahrenheit (°F) (as per local practice) throughout the study, at all major visit types, over the full observation period.

    Time frame: up to 4 years

  42. Vital Signs: Body Temperature per cohort in all countries

    Body Temperature is measured in degrees Celsius (°C) or Fahrenheit (°F) (as per local practice) throughout the study, at all major visit types, over the full observation period.

    Time frame: up to 4 years

  43. Vital Signs: Weight per cohort and per country

    Weight is measured in kilograms (kg) throughout the study, at all major visit types, over the full observation period.

    Time frame: up to 4 years

  44. Vital Signs: Weight per cohort in all countries

    Weight is measured in kilograms (kg) throughout the study, at all major visit types, over the full observation period.

    Time frame: up to 4 years

  45. Vital Signs: Height per cohort and per country

    Height is measured in centimeters (cm) throughout the study, at all major visit types, over the full observation period.

    Time frame: up to 4 years

  46. Vital Signs: Height per cohort in all countries

    Height is measured in centimeters (cm) throughout the study, at all major visit types, over the full observation period.

    Time frame: up to 4 years

  47. Laboratory Parameters: Hematology (Hemoglobin) per cohort and per country

    Hemoglobin (g/dL)) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  48. Laboratory Parameters: Hematology (Hemoglobin) per cohort in all countries

    Hemoglobin (g/dL)) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  49. Laboratory Parameters: Hematology (WBC) per cohort and per country

    White Blood Cell Count (WBC) (x10\^9/L) is performed throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  50. Laboratory Parameters: Hematology (WBC) per cohort in all countries

    White Blood Cell Count (WBC) (x10\^9/L) is performed throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  51. Laboratory Parameters: Hematology (Platelet Count) per cohort and per country

    Platelet Count (x10\^9/L) is performed throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  52. Laboratory Parameters: Hematology (Platelet Count) per cohort in all countries

    Platelet Count (x10\^9/L) is performed throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  53. Laboratory Parameters: Clinical Chemistry (Creatinine) per cohort and per country

    Serum Creatinine (mg/dL or µmol/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  54. Laboratory Parameters: Clinical Chemistry (Creatinine) per cohort in all countries

    Serum Creatinine (mg/dL or µmol/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  55. Laboratory Parameters: Clinical Chemistry (ALT) per cohort and per country

    Alanine Aminotransferase (ALT) (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  56. Laboratory Parameters: Clinical Chemistry (ALT) per cohort in all countries

    Alanine Aminotransferase (ALT) (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  57. Laboratory Parameters: Clinical Chemistry (AST) per cohort and per country

    Aspartate Aminotransferase (AST) (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  58. Laboratory Parameters: Clinical Chemistry (AST) per cohort in all countries

    Aspartate Aminotransferase (AST) (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  59. Laboratory Parameters: Clinical Chemistry (Bilirubin) per cohort and per country

    Total Bilirubin (mg/dL or µmol/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  60. Laboratory Parameters: Clinical Chemistry (Bilirubin) per cohort in all countries

    Total Bilirubin (mg/dL or µmol/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  61. Laboratory Parameters: Clinical Chemistry (Alkaline Phosphatase) per cohort and per country

    Alkaline Phosphatase (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  62. Laboratory Parameters: Clinical Chemistry (Alkaline Phosphatase) per cohort in all countries

    Alkaline Phosphatase (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  63. Laboratory Parameters: Clinical Chemistry (PSA) per cohort and per country

    Prostate-Specific Antigen (PSA) (ng/mL) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

  64. Laboratory Parameters: Clinical Chemistry (PSA) per cohort in all countries

    Prostate-Specific Antigen (PSA) (ng/mL) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.

    Time frame: up to 4 years

07

Study locations

10 of 16 sites recruiting
  • Many Locations
    Many Locations, Belgium
    Recruiting
  • Many Locations
    Many Locations, Finland
    Recruiting
  • Many Locations
    Many Locations, France
    Recruiting
  • Many Locations
    Many Locations, Germany
    Not yet recruiting
  • Many Locations
    Many Locations, Greece
    Recruiting
  • Many Locations
    Many Locations, Israel
    Recruiting
  • Many Locations
    Many Locations, Italy
    Recruiting
  • Many Locations
    Many Locations, Lithuania
    Not yet recruiting
  • Many Locations
    Many Locations, Norway
    Not yet recruiting
  • Many Locations
    Many Locations, Poland
    Recruiting
  • Many Locations
    Many Locations, Portugal
    Not yet recruiting
  • Many Locations
    Many Locations, Saudi Arabia
    Not yet recruiting
  • Many Locations
    Many Locations, Spain
    Recruiting
  • Many Locations
    Many Locations, Sweden
    Not yet recruiting
  • Many Locations
    Many Locations, Switzerland
    Recruiting
  • Many Locations
    Many Locations, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 47 months is close to that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 15, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Jun 30, 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 19, 2026
Sites
16 sites added, 16 sites removed
Show 16 added (1 Belgium, 1 Finland, 1 France, 1 Germany, 1 Greece, 1 Israel, 1 Italy, 1 Lithuania, 1 Norway, 1 Poland, 1 Portugal, 1 Saudi Arabia, 1 Spain, 1 Sweden, 1 Switzerland, 1 United Kingdom)
  • Many Locations · Many Locations, Belgium
  • Many Locations · Many Locations, Finland
  • Many Locations · Many Locations, France
  • Many Locations · Many Locations, Germany
  • Many Locations · Many Locations, Greece
  • Many Locations · Many Locations, Israel
  • Many Locations · Many Locations, Italy
  • Many Locations · Many Locations, Lithuania
  • Many Locations · Many Locations, Norway
  • Many Locations · Many Locations, Poland
  • Many Locations · Many Locations, Portugal
  • Many Locations · Many Locations, Saudi Arabia
  • Many Locations · Many Locations, Spain
  • Many Locations · Many Locations, Sweden
  • Many Locations · Many Locations, Switzerland
  • Many Locations · Many Locations, United Kingdom
Show 16 removed
  • Many Locations · Multiple Locations, Belgium
  • Many Locations · Multiple Locations, Finland
  • Many Locations · Multiple Locations, France
  • Many Locations · Multiple Locations, Germany
  • Many Locations · Multiple Locations, Greece
  • Many Locations · Multiple Locations, Israel
  • Many Locations · Multiple Locations, Italy
  • Many Locations · Multiple Locations, Lithuania
  • Many Locations · Multiple Locations, Norway
  • Many Locations · Multiple Locations, Poland
  • Many Locations · Multiple Locations, Portugal
  • Many Locations · Multiple Locations, Saudi Arabia
  • Many Locations · Multiple Locations, Spain
  • Many Locations · Multiple Locations, Sweden
  • Many Locations · Multiple Locations, Switzerland
  • Many Locations · Multiple Locations, United Kingdom
Oct 19, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedAny prior treatment with second-generation androgen receptor (AR) inhibitors (such as enzalutamide, apalutamide, or other investigational AR inhibitors), CYP17 inhibitorscytochrome P17 enzyme inhibitor (except prior abiraterone acetate if discontinued at least 24 months before metastatic diagnosis) or other investigational CYP17CYP 17 enzyme inhibitors) as antineoplastic treatment for prostate cancer.
Oct 19, 2026
Contact
Study contact now listed: added c•••@bayer.com · •••2937. See the current contact
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Recruiting
    16 sites added, 16 sites removed
    Show 16 added (1 Belgium, 1 Finland, 1 France, 1 Germany, 1 Greece, 1 Israel, 1 Italy, 1 Lithuania, 1 Norway, 1 Poland, 1 Portugal, 1 Saudi Arabia, 1 Spain, 1 Sweden, 1 Switzerland, 1 United Kingdom)
    • Many Locations · Many Locations, Belgium
    • Many Locations · Many Locations, Finland
    • Many Locations · Many Locations, France
    • Many Locations · Many Locations, Germany
    • Many Locations · Many Locations, Greece
    • Many Locations · Many Locations, Israel
    • Many Locations · Many Locations, Italy
    • Many Locations · Many Locations, Lithuania
    • Many Locations · Many Locations, Norway
    • Many Locations · Many Locations, Poland
    • Many Locations · Many Locations, Portugal
    • Many Locations · Many Locations, Saudi Arabia
    • Many Locations · Many Locations, Spain
    • Many Locations · Many Locations, Sweden
    • Many Locations · Many Locations, Switzerland
    • Many Locations · Many Locations, United Kingdom
    Show 16 removed
    • Many Locations · Multiple Locations, Belgium
    • Many Locations · Multiple Locations, Finland
    • Many Locations · Multiple Locations, France
    • Many Locations · Multiple Locations, Germany
    • Many Locations · Multiple Locations, Greece
    • Many Locations · Multiple Locations, Israel
    • Many Locations · Multiple Locations, Italy
    • Many Locations · Multiple Locations, Lithuania
    • Many Locations · Multiple Locations, Norway
    • Many Locations · Multiple Locations, Poland
    • Many Locations · Multiple Locations, Portugal
    • Many Locations · Multiple Locations, Saudi Arabia
    • Many Locations · Multiple Locations, Spain
    • Many Locations · Multiple Locations, Sweden
    • Many Locations · Multiple Locations, Switzerland
    • Many Locations · Multiple Locations, United Kingdom
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedAny prior treatment with second-generation androgen receptor (AR) inhibitors (such as enzalutamide, apalutamide, or other investigational AR inhibitors), CYP17 inhibitorscytochrome P17 enzyme inhibitor (except prior abiraterone acetate if discontinued at least 24 months before metastatic diagnosis) or other investigational CYP17CYP 17 enzyme inhibitors) as antineoplastic treatment for prostate cancer.
    Contact Study contact now listed: added c•••@bayer.com · •••2937. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07344779
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Jan 29, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
(+)1-888-84 22937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion